| Unique ID issued by UMIN | UMIN000018106 |
|---|---|
| Receipt number | R000020961 |
| Scientific Title | Treatment outcomes in wet age-related macular degeneration using a Treat-and-Extend regimen. |
| Date of disclosure of the study information | 2015/06/26 |
| Last modified on | 2026/07/14 17:02:21 |
Treatment outcomes in wet age-related macular degeneration using a Treat-and-Extend regimen.
Treatment outcomes in wet AMD using Treat-and-Extend regimen.
Treatment outcomes in wet age-related macular degeneration using a Treat-and-Extend regimen.
Treatment outcomes in wet AMD using Treat-and-Extend regimen.
| Japan |
Age-related macular degeneration
| Ophthalmology |
Others
NO
To investigate the efficacy of intravitreal anti-VEGF agents using Treat & Extend regimen in patients with wet AMD
Efficacy
Change of visual acuity at month 12,24,36.
The average treatment number according to the medicine , central macular thickness, change of leakage in retinal region, leakage from a polyp, leakage from choroidal neovascularization, subretinal fluid , the rate of incident and the enlargement of the geographic atrophy
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
| Medicine |
Eylea (aflibercept)
Lucentis(ranibizumab)
Macugen(Pegaptanib sodium)
| 45 | years-old | <= |
| Not applicable |
Male and Female
1) BCVA: 0.1-1.0
2) AMD with subfoveal fluid on fluorescent angiography, indocyanine green angiography and/or optical coherence tomography
3) Willingness to provide written informed consent
4) outpatient
1) Greatest Linear Dimension (GLD) of the total lesion area <12 Macular Photocoagulation Study Disc Areas
2) Presence of subretinal hemorrhage, scar or macular fibrosis (>50% lesion area)
3) Prior treatment with anti-VEGF drug, photodynamic therapy
4) Prior treatment with dexamethasone (<6 months) or triamcinolone (<30 days), intraocular surgery (<3 months)
5) Active intraocular inflammation
6) Hypersensitivity or allergy to fluorescein or indocyanine green, clinically significant drug allergy or known hypersensitivity to therapeutic or diagnostic protein products
7) Patient who the doctor in charge judges are ineligible for the study
150
| 1st name | Rie |
| Middle name | |
| Last name | Osaka |
Kagawa university faculty of medicine
Department of Ophthalmology
761-0793
1750-1 Ikenobe Miki-cho, Kagawa 761-0793, Japan
087-891-2211
osaka.rie@kagawa-u.ac.jp
| 1st name | Rie |
| Middle name | |
| Last name | Osaka |
Kagawa university faculty of medicine
Department of Ophthalmology
761-0793
1750-1 Ikenobe Miki-cho, Kagawa 761-0793, Japan
087-891-2211
ganka@med.kagawa-u.ac.jp
Department of Ophthalmology, Kagawa university faculty of medicine
none
Self funding
Ethics committee, Kagawa university faculty of medicine
1750-1 Ikenobe Miki-cho, Kagawa 761-0793, Japan
087-898-5111
chosa@med.kagawa-u.ac.jp
NO
| 2015 | Year | 06 | Month | 26 | Day |
Analysis and the publication of results were not achieved.
Unpublished
Analysis and the publication of results were not achieved.
86
In this study, consent had been obtained from a total of 86 participants. However, maintaining the research implementation structure became difficult after the primary researcher resigned during the course of the project. The decision to discontinue the study was made due to the absence of a researcher to play a central role and the difficulty in establishing a sufficient framework to carry out the originally planned research and analysis.
| 2026 | Year | 07 | Month | 14 | Day |
It was not possible to complete the analysis.
It was not possible to complete the analysis.
It was not possible to complete the analysis.
It was not possible to complete the analysis.
Terminated
| 2015 | Year | 06 | Month | 22 | Day |
| 2015 | Year | 06 | Month | 22 | Day |
| 2015 | Year | 06 | Month | 26 | Day |
| 2021 | Year | 07 | Month | 31 | Day |
| 2022 | Year | 07 | Month | 31 | Day |
| 2015 | Year | 06 | Month | 26 | Day |
| 2026 | Year | 07 | Month | 14 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000020961